Home » Progenics Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Progenics Pharmaceuticals Announces Pricing of Public Offering of Common Stock
April 1, 2005
Progenics Pharmaceuticals, Inc. announced the pricing of an underwritten public
offering of 2 million shares of its common stock pursuant to an effective shelf
registration statement. CIBC World Markets and UBS Investment Bank acted as
joint book-running managers for the offering. The price to the public is $15.25,
and proceeds to the company from the offering, net of expenses, are expected
to be approximately $29.3 million.
Yahoo
News
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
21Oct